New treatment to help recover from stroke by targeting specific brain receptors
Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
['FUNDING_SBIR_1'] · EPIGEN BIOSCIENCES, INC. · NIH-10921119
This study is testing a new treatment that helps the brain heal after a stroke by using a special product to boost certain receptors, and it's designed for people recovering from a stroke who are looking for better recovery options.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EPIGEN BIOSCIENCES, INC. (nih funded) |
| Locations | 1 site (SAN DIEGO, UNITED STATES) |
| Trial ID | NIH-10921119 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel product that modulates alpha7 nicotinic receptors to aid in recovery after a stroke. The approach involves using positive allosteric modulators to activate these receptors, which have shown potential in reducing neuroinflammation and promoting healing in preclinical models. By targeting the underlying mechanisms of neurodegeneration, the research aims to provide a pharmacotherapeutic option for stroke recovery, which is currently lacking. Patients may be involved in trials to assess the safety and efficacy of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals who have recently experienced an acute ischemic stroke.
Not a fit: Patients who have not had a stroke or those with chronic neurological conditions unrelated to stroke may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new medication that significantly improves recovery outcomes for stroke patients.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting alpha7 nicotinic receptors in rodent models, indicating potential for success in human applications.
Where this research is happening
SAN DIEGO, UNITED STATES
- EPIGEN BIOSCIENCES, INC. — SAN DIEGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: UTESHEV, VICTOR V — EPIGEN BIOSCIENCES, INC.
- Study coordinator: UTESHEV, VICTOR V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.